Does deep brain stimulation of the subthalamic nucleus induce metabolic syndrome in Parkinson's disease?

e-SPEN

Volumn 6, Issue 3, 2011, Pages

  Rieu, Isabelle ^a,b   Pereira, Bruno ^a   Derost, Philippe ^a,b   Ulla, Miguel ^a,b   Marques, Ana ^a,b   Lemaire, Jean Jacques ^a   Boirie, Yves ^a,b,c   Durif, Franck ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CRNH AUVERGNE   (France)

Author keywords

Body weight; Deep brain stimulation; Metabolic syndrome; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVODOPA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN DEPTH STIMULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; PARKINSON DISEASE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SUBTHALAMIC NUCLEUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 79957707210     PISSN: 17514991     EISSN: 17514991     Source Type: Journal    
DOI: 10.1016/j.eclnm.2011.03.002     Document Type: Article

References (34)

1. Derost P.P., Ouchchane L., Morand D., et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?. Neurology 2007, 68:1345-1355.
2. Barichella M., Marczewska A.M., Mariani C., et al. Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Mov Disord 2003, 18:1337-1340.
3. Macia F., Perlemoine C., Coman I., et al. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 2004, 19:206-212.
4. Tuite P.J., Maxwell R.E., Ikramuddin S., et al. Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. Parkinsonism Relat Disord 2005, 11:247-252.
5. Visser-Vandewalle V., Van der Linden C., Temel Y., et al. Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: a four-year follow-up study. Parkinsonism Relat Disord 2005, 11:157-165.
6. Novakova L., Ruzicka E., Jech R., et al. Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neuro Endocrinol Lett 2007, 28:21-25.
7. Montaurier C., Morio B., Bannier S., et al. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain 2007, 130:1808-1818.
8. Bannier S., Montaurier C., Derost P.P., et al. Overweight after deep brain stimulation of the subthalamic nucleus in Parkinson disease: long term follow-up. J Neurol Neurosurg Psychiatry 2009, 80:484-488.
9. Perlemoine C., Macia F., Tison F.A.U.X., et al. Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease. Br J Nutr 2005, 93:191-198.
10. Hughes A.J., Ben-Shlomo Y., Daniel S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
11. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, 153-163. MacMillan Health Care Information, Florham Park, NJ. S. Fahn, C.D. Marsden, D. Calne, N. Golstein (Eds.).
12. Folstein M.F., Folstein S.E., McHugh P.R. " Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
13. Schmidt R., Freidl W., Fazekas F., et al. The Mattis Dementia rating scale: normative data from 1,001 healthy volunteers. Neurology 1994, 44:964-966.
14. Lemaire J.J., Coste J., Ouchane L., et al. Brain mapping in stereotactic surgery: a brief overview from the probabilistic targeting to the patient-based anatomic mapping. Neuroimage 2007, 37(Suppl. 1):S109-S115.
15. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 2006, 28:1-12.
16. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
17. Wakabayashi K., Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997, 38(Suppl. 2):2-7.
18. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993, 69:125-130.
19. Pressley J.C., Louis E.D., Tang M.X., et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 2003, 60:87-93.
20. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004, 82:510-529.
21. Hu G., Jousilahti P., Bidel S., et al. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007, 30:842-847.
22. Scigliano G., Musicco M., Soliveri P., et al. Reduced risk factors for vascular disorders in Parkinson's disease patients: a case-control study. Stroke 2006, 37:1184-1188.
23. Simon K.C., Chen H., Schwarzschild M., et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson's disease. Neurology 2007, 69:1688-1695.
24. Becker C., Brobert G.P., Johansson S., et al. Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 2008, 31:1808-1812.
25. Pocai A., Lam T.K., Gutierrez-Juarez R., et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 2005, 434:1026-1031.
26. Lam T.K., Gutierrez-Juarez R., Pocai A., et al. Regulation of blood glucose by hypothalamic pyruvate metabolism. Science 2005, 309:943-947.
27. Morton G.J. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007, 583:437-443.
28. Ludwig J., Remien P., Guballa C., et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:742-745.
29. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
30. Scigliano G., Ronchetti G., Girotti F. Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizophrenia and Parkinson's disease. Neurol Sci 2008, 29:15-21.
31. Lam T.K., Pocai A., Gutierrez-Juarez R., et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005, 11:320-327.
32. He W., Lam T.K., Obici S., et al. Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci 2006, 9:227-233.
33. Stafford J.M., Yu F., Printz R., et al. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 2008, 57:1482-1490.
34. Cornier M.A., Dabelea D., Hernandez T.L., et al. The metabolic syndrome. Endocr Rev 2008, 29:777-822.